Erin Quirk Terns Pharmaceuticals, Inc. (TERN) insider trading activity
Erin Quirk is President, Head of R&D of Terns Pharmaceuticals, Inc.. Currently has a direct ownership of 75,000 shares of TERN, which is worth approximately $426,000. The most recent transaction as insider was on Jan 23, 2024, when has been sold 75,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).
Shares Held (Direct Ownership)
75K
0%
3M change
n/a
12M change
Total Value Held
$426,000
EQ
Erin Quirk
President, Head of R&D
Foster City, CA